Parkwalk invested in Horizon Discovery in May 2013. The company had a successful IPO in March 2014, raising £40m to list with a market capitalisation of £120m. The flotation was priced at over 100% above the price at which Parkwalk invested.
Horizon’s basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges of translational researchers.
Horizon aspires to provide solutions that unlock the promise of the human genome project for the benefit of scientific researchers, patients and society; provide powerful research tools to advance the development of personalized medicines; provide molecular reference standards and support better healthcare outcomes for patients.